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ABSTRACT Two related but differentially expressed po-
tential membrane proteins of Epstein-Barr virus are encoded
by the same reading frame in the EcoRI D het region of the viral
genome. Potential antigenic sites in the amino acid sequence of
these proteins were selected by computer-aided prediction of
the secondary structure and two oligopeptides corresponding to
regions located in different parts of the proteins were synthe-
sized chemically. Rabbit antisera to these peptides were used
for immunoprecipitation of the native viral proteins from
Epstein-Barr virus-positive cell lines from various sources.
Both predicted membrane proteins could be precipitated from
cell lines that had been transformed in vitro with EBV or from
cell lines derived from infectious mononucleosis patients. In cell
lines established from Burkitt lymphoma, only the smaller
polypeptide, which lacks 138 amino acids from the amino
terminus, could be identified. Using the synthetic peptides as
antigens in ELISA, we detected elevated antibody titers in sera
from patients with infectious mononucleosis and naso-
pharyngeal carcinoma.
Epstein-Barr virus (EBV), a human herpesvirus, causes
infectious mononucleosis (1, 2) as a primary disease and
remains latent in human B lymphocytes, transforming them
into lymphoblastoid cells that proliferate indefinitely upon
cultivation in vitro (3, 4). EBV has also been found to be
associated with African Burkitt lymphoma (5-7) and
nasopharyngeal carcinoma (8, 9) and with polyclonal
lymphomas in immunosuppressed individuals (10).
At least five regions of the viral genome are transcribed
during latency: the small unique (Us) region is transcribed to
give EBER RNAs (11); the internal repeat region with
neighboring sequences encodes the nuclear antigen EBNA2
(12); the BamHI fragment-K region encodes EBNA1 (13, 14);
a region in the long unique (UL) region codes for EBNA3 (15);
and the region of the EcoRI D het fragment at the right end
of the viral DNA codes for a potential membrane protein
(16-18). Two related membrane proteins were proposed to be
expressed from this reading frame, BNLF1 (19), which has
promoters with differential activity and a single 3'-terminal
end. The shorter of the two proteins would lack 138 amino
acids from the amino terminus (ref. 20; Fig. 1). Further, it was
predicted that the larger protein would have a highly charged
amino terminus followed by a hydrophobic domain, consist-
ing of six transmembrane regions, and a large hydrophilic
carboxyl-terminal region. The existence of an EBV-associa-
ted membrane protein in latently infected cells was also
suggested by studies ofcytotoxic T-cell clones (21-24), which
recognize an antigen, found only on EBV-infected cells,
known as lymphocyte-determined membrane antigen
(LYDMA). The biochemical properties of this antigen are not
known.
For further characterization of the EBV-encoded mem-
brane antigen in latently infected cells ("latent membrane
antigen" or BNLF1-MA), we synthesized oligopeptides
corresponding to the amino-terminal part and to the repeat
unit that is part of the large hydrophilic carboxyl-terminal
domain. (The first one should only be present in the larger
protein, whereas the latter is a part ofboth proteins.) Antisera
against the peptides were used for immunoprecipitation ofthe
native proteins from various cell lines.
The peptides were also used as antigens in ELISA assays,
in which sera from patients suffering from infectious mono-
nucleosis and the EBV-related nasopharyngeal carcinoma
were tested for the presence of the respective antibodies.
MATERIALS AND METHODS
Computer-Predicted Analysis of the Secondary Structure.
The secondary structure of the latent membrane protein was
predicted by a program, written for a VAX 750 computer,
based on suggestions by Cohen et al. (25), using the algo-
rithms of Chou and Fasman (26) or Garnier et al. (27) to
predict secondary structures. These predictions were super-
imposed with the values oflocal hydrophilicity determined by
the method of Hopp and Woods (28). As alternatives, values
for surface probability [modified from Emini et al. (29)] or
flexibility (30) can be superimposed. The probability of the
occurrence of a-helices, A-pleated sheets, random coils, and
1-turn regions was evaluated using stringent conditions (31).
The parameters for hydrophilicity were averaged over five
amino acid residues, with a limit of 0.7. a-Helical structures
in a hydrophilic or nonhydrophobic environment are likely
candidates for antigenic sites, since they frequently form
loop-like structures at the protein surface.
Peptide Synthesis. Two peptides were synthesized (for
sequence and location, see Fig. 1C) using the Merrifield
solid-phase methods (32) with the following modifications.
Before and after deprotection of N-t-butoxycarbonyl (N-t-
Boc) amino acids, a series of three washes, with methylene
chloride, absolute ethanol, and methylene chloride, respec-
tively, was used; deprotection of N-t-Boc amino acids was
done with 25% trifluoroacetic acid in methylene chloride.
Completeness of deprotection and coupling reactions were
monitored by the ninhydrin color test (33). All coupling
reactions were carried out using a 4-fold excess of N-t-Boc
amino acids and a 3-fold excess of dicyclohexylcarbodiimide
(Aldrich) according to the amount of the first amino acid. All
N-t-Boc amino acids were purchased from Sigma; N-t-
butoxycarbonyl-4-methoxybenzylcysteine-0-resin was pur-
chased from Peninsula Laboratories (St. Helens, England).
Abbreviations: EBV, Epstein-Barr virus; EBNA, EBV-encoded
nuclear antigen; KLH, keyhole limpet hemocyanin.
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FIG. 1. (A) Schematic diagram of the EBV genome indicating terminal repeats (TR), unique regions (U), and internal repeats (IR). (B)
Organization and transcription of the right-hand end of the U5 region ofEBV. Numbering is from the standard sequence, representing thousands
ofbase pairs from the left end ofthe entire viral genome. Transcripts ofthis region are represented with boxes showing predicted protein-encoding
regions. (C) Chou-Fasman prediction of the structure of the proteins encoded by the BNLF1 reading frame. The translation starts of the two
predicted gene products and the amino acid sequences (standard one-letter abbreviations) of the peptides synthesized are indicated. Probability
of occurrence of a-helices (e.g., arrowheads a), /3-pleated sheets (arrowhead b), random coils (arrowheads c), and (3-turn regions (arrowheads
d) was evaluated using stringent conditions. The parameters for hydrophilicity were averaged over five amino acid residues with a limit of 0.7
(hydrophilic regions are shown as ovals, and hydrophobic regions, as diamonds).
The side chains were cleaved from the resin in thioanisole
suspension at 0C with anhydrous hydrogen fluoride
(Matheson). After precipitation and extensive washing with
ethyl acetate, the peptide was lyophilized, extracted with
1.5% NH4HCO3, and purified by molecular sieving (Bio-Gel
P-4 column, Bio-Rad).
Immunization of Rabbits. For the production of antisera,
two alternative procedures were used. (i) The peptides were
coupled to keyhole limpet hemocyanin (KLH) (34) with
m-maleimidobenzoyl-N-hydroxysuccinimide ester. Since
this coupling reaction requires the presence of a thiol group,
cysteine was included as the first amino acid at the carboxyl
terminus. (it) The amino acids glycine, glycine, and lysine
(Lys-Gly-Gly) were covalently linked to the amino terminus
of the peptide, and both amino groups of the terminal lysine
were esterified with palmitic acid by following the procedure
of solid-phase synthesis (35).
Rabbits were inoculated subcutaneously with a 1-ml emul-
sion of antigen (200 ug of the palmitoylated peptides or 400
Ag ofthe KLH conjugate) in phosphate-buffered saline (PBS:
130 mM NaCl/2.7 mM KCl/8 mM Na2HPO4/1.5 mM
KH2PO4/0.9 mM CaCl2/0.5 mM MgCl2, pH 7.2) plus com-
plete Freund's adjuvant; booster injections were given at
intervals of 3 weeks with incomplete Freund's adjuvant.
ELISA. Either of the two peptides (20 pug per well, 96-well
plate, Dynatech) was coupled in 50 1.d of 0.2 M sodium
carbonate buffer (pH 9.5) overnight. The plates were incu-
bated with gelatin solution (5 mg/ml) for 1 hr and then
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were incubated 2 hr with 50 A.l of serum diluted in PBS/0.5%
Tween 20, followed by incubation with peroxidase-labeled
second antibody [rabbit anti-human IgG, Dako (Santa
Barbara, CA), or goat anti-human IgA, Teko] diluted 1:500 in
PBS/0.5% Tween 20. Staining was done with o-phenylene-
diamine (1 mg/ml in phosphate buffer, pH 6.0) and was
stopped after 10 min with 1 M H2SO4. The optical density was
determined at 486 nm.
Immunoprecipitation. Cells were grown in RPMI 1640
medium with 10% fetal bovine serum and, depending on the
experiment, treated with phorbol 12-myristate 13-acetate (40
ng/ml; Sigma) and butyric acid (3 mM) or with phosphono-
acetic acid (200 ,ug/ml) or cycloheximide (50 kug/ml). After
incubation with [35S]methionine (20 AGCi/ml; 1 Ci = 37 GBq)
or [14C]leucine (2 ,uCi/ml) (Amersham-Buchler, Braun-
schweig, F.R.G.) for various intervals, cells were washed,
suspended in immunoprecipitation buffer [0.5% Nonidet
P-40/20 mM Tris Cl, pH 9.0/300 mM NaCl/1 mM CaCl2/0.5
mM MgCl2/2 mM EDTA/10% (vol/vol) glycerol], and lysed
by sonication. Lysates were cleared of nonspecifically re-
acting material by incubation with 10 ,ul of negative rabbit
serum and 3 mg of protein A-Sepharose beads (Pharmacia)
per 106 cells. The beads with the nonspecific immunocom-
plexes were removed, the supernatants were incubated with
10 ,ul of positive serum (preadsorbed with an extract of 107
EBV-negative BJAB cells) per 106 cells, 3 mg of protein
A-Sepharose beads were added. The beads with the bound
immunocomplexes were pelleted, washed, suspended in
solubilization buffer (2% NaDodSO4/3% sucrose/5% 2-
mercaptoethanol/20 mM Tris Cl, pH 7.0, containing
bromphenol blue), heated at 100°C, and subjected to elec-
trophoresis as described (36).
RESULTS
Selection of Peptide Sequence and Production of the Respec-
tive Antisera. The computer-predicted analysis of the sec-
ondary structure of proteins combined with the values of
hydrophobicity allowed the identification of highly antigenic
regions ofthe EBV latent membrane proteins expressed from
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the reading frame BNLF1. To study the different expression
of the two putative proteins (20), we synthesized peptides
corresponding to the sequence of the hydrophilic P-turn
region from the amino terminus of the large protein (peptide
1-18) and to the sequence of a hydrophilic repeat unit
(peptide 252-263) that is located downstream from the
transmembrane region and should be a common antigenic
epitope of both forms of the membrane proteins. The se-
quences of the peptides are indicated in Fig. 1C.
Antisera against the peptides were raised in rabbits immu-
nized with dipalmitoyllysylglyrylglycyl or with KLH-peptide
conjugate. When tested in ELISA assays, the sera showed
titers up to 1:200,000 against the individual peptides.
Screening of Human Sera for Peptide Antibodies. To iden-
tify antibodies against oligopeptides derived from the latent
membrane antigens, peptides 1-18 and 252-263 were used as
antigens in ELISAs to screen sera of healthy, EBV-positive
individuals [anti-VCA (viral capsid antigen) IgG titer 1:32 to
1:128, EBNA-positive in immunofluorescence tests];
nasopharyngeal carcinoma patients [anti-VCA IgG titer 1:32
to 1:2056, anti-EA (early antigen) IgA titer 1:16 to 1:128,
EBNA-positive]; Burkitt lymphoma patients [anti-VCA IgG
titer 1:1280, anti-EA-DR (restricted EA) IgG titer 1:10 to
1:2560, EBNA-positive]; patients with fresh EBV infections
(anti-VCA IgG titer 1:18 to 1:64, anti-VCA IgM titer 1:16 to
1:128, anti-EA IgG and IgA titer 1:16 to 1:128, EBNA-
negative); and EBV-negative individuals. All sera were used
at a dilution of 1:50 in the ELISA, and the optical density was
determined at 486 nm. The sera of patients with
nasopharyngeal carcinoma or fresh EBV infection reacted
very strongly with the amino-terminal epitope peptide 1-18.
Those of healthy individuals showed almost no reaction
compared to those of EBV-negative persons (Fig. 2); sera of
Burkitt lymphoma patients showed a slightly greater reac-
tion. With peptide 252-263 as antigen, the same sera of
nasopharyngeal carcinoma, Burkitt lymphoma, and fresh
infectious mononucleosis patients showed only slightly great-
er reactions than did sera of healthy individuals.
Immunoprecipitation of Latent Membrane Proteins from
Various Cell Lines. Rabbit antisera raised against both pep-
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FIG. 2. Distribution of the values for optical density obtained by ELISA using the various groups of human sera. Sera were from
EBV-negative individuals (group A), healthy EBV-positive individuals (group B), nasopharyngeal carcinoma patients (group C), or patients with
fresh EBV infections (group D). All sera were used at a dilution of 1:50 in phosphate-buffered saline. Peroxidase-conjugated second antibodies
were goat anti-human IgA (Left) or rabbit anti-human IgG (Right). The antigen was underivatized peptide 1-18.
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tides were used to precipitate [35S]methionine-labeled
polypeptides from the Burkitt lymphoma-derived cell lines
Raji (37), Jijoye (38), Namalwa (39), and P3HR1 (40); from
the in vitro-transformed marmoset cell line B95-8 (41), from
the in vitro-transformed human cord-blood lines CB176-
HK975 (provided by G. Lenoir, International Agency for
Research on Cancer, Lyon, France) and J-Aba (42); and from
two spontaneous cell lines derived from infectious mononu-
cleosis patients (RB and RS). BJAB (43) and Ramos (44) were
used as EBV-negative lines. Antiserum against the amino-
terminal peptide 1-18 specifically immunoprecipitated pro-
teins of 60-70 kDa from lysates of in vitro-transformed and
spontaneous cell lines (Fig. 3A). The variation in molecular
mass is likely due to variations in the number of repeat units
present in the viral genome of the various cell lines (17). No
protein that reacted specifically with the antiserum to peptide
1-18 was found in any of the Burkitt lymphoma lines. The
result was similar for EBV-negative cell lines.
When the serum directed against peptide 252-263 from the
amino acid repeat at the carboxyl-terminal part of the
predicted sequence was used for immunoprecipitation (Fig.
3B), a protein with the same molecular mass range as
described above (60-70 kDa) was identified in the in vitro-
transformed lines B95-8, CB176HK975, and (data not shown)
J-Aba and in the infectious mononucleosis lines RB and (data
not shown) RS, together with a second protein of apparent
molecular mass ranging from 50 to 60 kDa. Polypeptides of
50. 60 kDa were also detected in the Burkitt lymphoma cells
Raji, Jijoye, and Namalwa; in P3HR1 we found only a very
weak reaction. No protein was identified in the EBV-negative
cell lines (Fig. 3 A and B).
The apparent sizes of the proteins in NaDodSO4/
polyacrylamide gels, 60-70 kDa and 50-60 kDa, were differ-
ent from the predicted values (42 kDa and 28 kDa, respec-
tively). This anomalous behavior of the polypeptides may be
due to the high content of aspartic acid and proline and was
also reported by other groups (17, 18). Identification of these
polypeptides was clearer when [14C]leucine was used for
labeling, which is compatible with the presence of only 3
methionine but 34 leucine residues in the sequence.
When cells were treated with phorbol 12-myristate 13-
acetate and butyric acid to induce the synthesis of late viral
gene products, no polypeptides were identified by immuno-
precipitation with the anti-peptide sera (Fig. 3C). A similar
result was obtained when protein synthesis was blocked by
cycloheximide, followed by a labeling period when further
RNA synthesis was inhibited by the addition of actinomycin
D. When viral DNA synthesis was inhibited by phosphono-
acetic acid, the latent membrane proteins were detected in
the treated cells. We conclude that the identified proteins
belong to a group of viral gene products whose synthesis is
blocked by viral DNA synthesis.
DISCUSSION
This work presents data for a differential expression of
protein products ofthe open reading frame BNLF1 (19) in the
EcoRI fragment-D region of EBV. This reading frame has
been shown to code for two viral transcripts (20), the larger
of which has been reported to be a latent membrane protein
(17, 18), which may be the still-unidentified target antigen of
cytotoxic T cells directed against EBV-infected cells. Taking
into account computer-predicted analysis of secondary struc-
tures and hydrophilicity of amino acids, we synthesized
antigenic epitopes from various regions of the protein.
Antibodies prepared against the peptides were able to iden-
tify the original viral products. It could be shown that these
proteins are produced with varying molecular mass according
to the number of repeat units present in the cell lines; similar
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FIG. 3. (A and B) Immunoprecipitation of lysates from various cell lines (indicated above the lanes). Cells were labeled with [14C]leucine
(2 ,uCi/ml) for 6 hr, washed, suspended in immunoprecipitation buffer, and sonicated. Lysates were incubated first with negative rabbit serum
and protein A-Sepharose beads. After the beads with the nonspecific complexes were removed, the labeled extracts were incubated with sera
directed against the amino-terminal part of the latent membrane protein (anti-1-18, A) or against the internal part (anti-252-263, B). After the
immunocomplexes were bound to protein A-Sepharose beads, the beads were washed, suspended in electrophoresis buffer, and heated at 1000C,
and the labeled proteins were analyzed by NaDodSO4/PAGE followed by autoradiography. Black triangles indicate specifically immunoprecipi-
tated polypeptides discussed in text. High background is due to the very long exposure (2 months) and the labeling with [14C]leucine. (C)
Immunoprecipitation of proteins from [35S]methionine-labeled cells, using antiserum to peptide 1-18. Lanes 1: cells not treated, labeled for 4
hr. Lanes 2: cells treated with cycloheximide (50 ,g/ml) for 6 hr, then labeled in the presence of actinomycin D (2 ,ug/ml) for 4 hr. Lanes 3:
cells treated with phosphonoacetic acid for 24 hr, then labeled for 4 hr. Lanes 4: cells treated with phorbol 12-myristate 13-acetate (40 ,ug/ml)
and butyric acid (3 mM) for 24 hr, then labeled for 4 hr.
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results were found by Hennessy et al. (17). In addition, we
were able to show that this region of the EBV genome is
differentially expressed in Burkitt lymphoma cells and EBV-
producer cell lines. Burkitt lymphoma cells, in which the viral
DNA is present in a latent state and which do not synthesize
EBV, do not express the first part of the BNLF1 reading
frame, suggesting that only the second proposed promoter(20) is used for the start of transcription. This smaller protein(50-60 kDa) was detected in all EBV-positive cell lines and
is a truncated form of the larger one (60-70 kDa), lacking the
first hydrophilic domain and four of the proposed transmem-
brane regions. In precipitations with anti-peptide 1-18 serum,
a protein of about 32 kDa was identified in B95-8 and
CB176HK1975 cells. Since no protein in the BNLF1 frame
could be classed with this product, we assume that the
32-kDa protein either is associated with the 60- to 70-kDa
product in the membrane and therefore coprecipitates or is a
cellular product with a similar antigenic determinant.
If the latent membrane protein complex described in our
experiments is correlated to the lymphocyte-determined
membrane antigen (LYDMA) on EBV-producing cells, the
target for cytotoxic-T-cell recognition should be located in
the first part of the protein, possibly in one of the two turn
regions separating transmembrane regions 1 and 2 and
transmembrane regions 3 and 4, respectively, which probably
are exposed at the surface of the cell, since-due to the lack
of a signal peptide-the highly charged amino terminus is not
likely to be located on the outside of the cell. After cytotoxic-
T-cell recognition and lysis of the LYDMA-positive cells, the
amino terminus may be exposed to the immune system of the
host. As a consequence, in sera derived from patients with
fresh EBV infection or nasopharyngeal carcinoma, we were
able to detect elevated antibody titers for the amino-terminal
peptide from the latent membrane protein. The fact that some
sera from Burkitt lymphoma patients reacted with peptide
1-18 as well is not surprising, since Burkitt lymphoma
patients possess, besides the lymphoma cells, peripheral
lymphocytes containing EBV genomes without showing the
lymphoma genotype or phenotype.
Another possibility is that this protein alone is not suffi-
cient to elicit cytotoxic-T-cell reaction. The highly charged
amino terminus and the following hydrophobic transmem-
brane part may be involved in complex formations and
conformational changes with other components of the cell
membrane, which then may be the target for the T-cell
recognition.
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